Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Patent CN113636968B enables high-purity API intermediates through ruthenium-catalyzed synthesis with enhanced atom economy and reduced manufacturing costs.
Patent CN113683595B enables cost-effective production of high-purity triazole intermediates through sulfur-promoted catalysis without hazardous reagents.
Patent CN116813544B enables catalyst-free quinoline synthesis with high atom economy ensuring cost reduction in API manufacturing and reliable supply chain continuity.
Patent CN115286578B enables high-purity trifluoromethyl pyrazole intermediates through room temperature metal-free catalysis, reducing manufacturing costs and ensuring reliable pharmaceutical supply chains.
Patent CN117164506B enables high-purity indeno[1,2-b]indole intermediates through streamlined catalysis, reducing supply chain lead times and manufacturing costs.
Patent CN115872905A enables high-purity API intermediate production with TON=100,000, reducing manufacturing costs and supply chain lead time through green catalysis.
Novel molybdenum-copper catalyzed synthesis achieves high-purity triazole intermediates with 99% yield. Reduces lead time and manufacturing costs for pharmaceutical applications.
Novel iron-catalyzed synthesis enables high-purity quinazolinone intermediates with reduced manufacturing costs and reliable supply chain for pharmaceutical applications.
Patent CN106905349A enables one-step synthesis with high atom economy reducing lead time and manufacturing costs for pharmaceutical intermediates.
Novel four-step route with high stereoselectivity enables cost-effective API production and reliable supply chain for pharmaceutical manufacturers.
Novel palladium-catalyzed reductive aminocarbonylation enables high-purity chromane amide intermediates with simplified supply chain and reduced manufacturing costs.
Patent CN108191778B enables high-purity API intermediates through simplified one-pot process, reducing costs and lead times for pharmaceutical supply chains.
Patent CN111675662B enables cost-effective manufacturing of high-purity quinazolinone intermediates through iron-catalyzed cyclization with reliable supply chain integration.
Patent CN113045489A enables high-purity quinoline intermediates through dual-source catalysis, reducing lead time and manufacturing costs for pharmaceutical supply chains.
Patent CN113880781A enables high-purity trifluoromethyl triazole intermediates through glucose-based synthesis, reducing lead time and manufacturing costs for pharmaceutical supply chains.
Patent CN119874591B enables high-purity API intermediates through mild nickel catalysis, reducing lead time and manufacturing costs for pharmaceutical supply chains.
Patent CN112480015A delivers high-purity quinazolinone intermediates through streamlined one-pot synthesis, reducing lead time and manufacturing costs for pharmaceutical supply chains.
Patent CN118619879A enables high-purity trifluoromethyl enaminones through simplified rhodium catalysis, reducing lead time and manufacturing costs for pharmaceutical intermediates.
Patent CN110467579B enables heavy metal-free synthesis of high-purity triazoles with streamlined manufacturing and reliable supply chain benefits.
Patent CN115260080B enables high-purity indole-3-carboxamide production through efficient palladium-catalyzed carbonylation, reducing lead time and manufacturing costs for pharmaceutical intermediates.